Robert K. Weigle - 31 Jul 2026 Form 4 Insider Report for Tenon Medical, Inc. (TNON)

Reporting relationship: Director
Issuer ticker: TNON
Reported as of: 31 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Aug 2026, 16:52:29 UTC
Prior SEC filing: 05 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Robert Weigle

Key filing fact

Robert K. Weigle filed Form 4 for Tenon Medical, Inc. (TNON) on 04 Aug 2026.

Key facts

This page summarizes Robert K. Weigle's Form 4 filing for Tenon Medical, Inc. (TNON).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 04 Aug 2026, 16:52.

Change

Previous filing in this sequence was filed on 05 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001897664 Primary reporting owner

WEIGLE ROBERT K

Relationship: Director
Address: 104 COOPER COURT, LOS GATOS
Signature: /s/ Robert Weigle
Signature date: 04 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TNON transaction

Common Stock

Options Exercise

Transaction value
Shares: +10,732
Change %: +142%
Price: $0.000000^*
Shares after: 18,284
Date: 31 Jul 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TNON transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -10,732
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 31 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,732
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents conversion of 10,732 restricted stock units granted to the reporting person on October 13, 2025 into 10,732 shares of common stock of the Issuer on July 31, 2026.

Footnote F2

Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.